2.47
0.02 (0.82%)
| Previous Close | 2.45 |
| Open | 2.40 |
| Volume | 765,053 |
| Avg. Volume (3M) | 1,994,303 |
| Market Cap | 239,378,608 |
| Price / Sales | 5.75 |
| Price / Book | 1.53 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -259.60% |
| Operating Margin (TTM) | -402.93% |
| Diluted EPS (TTM) | -1.48 |
| Quarterly Revenue Growth (YOY) | 138.20% |
| Total Debt/Equity (MRQ) | 32.99% |
| Current Ratio (MRQ) | 5.70 |
| Operating Cash Flow (TTM) | -80.32 M |
| Levered Free Cash Flow (TTM) | -53.06 M |
| Return on Assets (TTM) | -20.30% |
| Return on Equity (TTM) | -45.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | C4 Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.79% |
| % Held by Institutions | 91.87% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Barclays, 304.86%) | Buy |
| 10.00 (Wells Fargo, 304.86%) | Buy | |
| Median | 10.00 (304.86%) | |
| Low | 6.00 (Stephens & Co., 142.92%) | Buy |
| Average | 8.67 (251.01%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 23 Sep 2025 | 10.00 (304.86%) | Buy | 2.59 |
| 17 Sep 2025 | 8.00 (223.89%) | Buy | 3.38 | |
| Wells Fargo | 23 Sep 2025 | 10.00 (304.86%) | Buy | 2.59 |
| Stephens & Co. | 22 Sep 2025 | 6.00 (142.91%) | Buy | 2.61 |
| 15 Sep 2025 | 6.00 (142.91%) | Buy | 3.57 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |